Review: taking Depakote er and Keppra together


Summary

Drug interactions are reported among people who take Depakote er and Keppra together. This review analyzes the effectiveness and drug interactions between Depakote er and Keppra. It is created by eHealthMe based on reports of 872 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Depakote er and Keppra >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Depakote Er

Depakote er has active ingredients of divalproex sodium. It is often used in bipolar disorder. (latest outcomes from Depakote er 3,580 users)

Keppra

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. (latest outcomes from Keppra 20,770 users)

On Jul, 27, 2016

872 people who take Depakote Er, Keppra are studied.


Number of reports submitted per year:

Depakote er and Keppra drug interactions.

Drug effectiveness over time:

Depakote Er:
  • < 1 month: 100.0% - (2 of 2 people)
  • 1 - 6 months: 25.0% - (1 of 4 people)
  • 6 - 12 months: 0.0% - (0 of 4 people)
  • 1 - 2 years: 62.0% - (5 of 8 people)
  • 2 - 5 years: 12.0% - (1 of 8 people)
  • 5 - 10 years: 90.0% - (9 of 10 people)
  • 10+ years: 70.0% - (7 of 10 people)
  • not specified: 0.0% - (0 of 1 people)
Keppra:
  • < 1 month: 50.0% - (1 of 2 people)
  • 1 - 6 months: 33.0% - (2 of 6 people)
  • 6 - 12 months: 55.0% - (5 of 9 people)
  • 1 - 2 years: 0.0% - (0 of 6 people)
  • 2 - 5 years: 30.0% - (4 of 13 people)
  • 5 - 10 years: 87.0% - (7 of 8 people)
  • 10+ years: 50.0% - (1 of 2 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Depakote Er:
  • female: 38.0% - (8 of 21 people)
  • male: 65.0% - (17 of 26 people)
Keppra:
  • female: 40.0% - (8 of 20 people)
  • male: 46.0% - (12 of 26 people)

Drug effectiveness by age:

Depakote Er:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 100.0% - (3 of 3 people)
  • 10-19: 41.0% - (5 of 12 people)
  • 20-29: 76.0% - (10 of 13 people)
  • 30-39: 37.0% - (3 of 8 people)
  • 40-49: 42.0% - (3 of 7 people)
  • 50-59: 33.0% - (1 of 3 people)
  • 60+: 0.0% - (0 of 1 people)
Keppra:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 100.0% - (2 of 2 people)
  • 10-19: 23.0% - (3 of 13 people)
  • 20-29: 58.0% - (7 of 12 people)
  • 30-39: 25.0% - (2 of 8 people)
  • 40-49: 71.0% - (5 of 7 people)
  • 50-59: 33.0% - (1 of 3 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • granulocytopenia
  • blood cholesterol increased
  • blood glucose increased
  • blood triglycerides increased
  • convulsion
  • haematocrit decreased
  • haemoglobin decreased
  • overdose
  • stevens-johnson syndrome
  • abnormal behaviour
1 - 6 months:
  • convulsion
  • drug ineffective
  • pyrexia
  • fall
  • syncope
  • confusional state
  • deep vein thrombosis
  • grand mal convulsion
  • pain
  • drug hypersensitivity
6 - 12 months:
  • asthenia
  • convulsion
  • tremor
  • weight decreased
  • atrial fibrillation
  • atrophy
  • cognitive disorder
  • gait disturbance
  • memory impairment
  • postictal paralysis
1 - 2 years:
  • somnolence
  • atrophy
  • cognitive disorder
  • gait disturbance
  • memory impairment
  • postictal paralysis
  • speech disorder
  • weight decreased
  • sedation
  • abnormal behaviour
2 - 5 years:
  • convulsion
  • dizziness
  • constipation
  • asthenia
  • gait disturbance
  • grand mal convulsion
  • pancytopenia
  • tremor
  • abnormal behaviour
  • amnesia
5 - 10 years:
  • arteriosclerosis coronary artery
  • cardiomegaly
  • cardiomyopathy
  • convulsion
  • coronary artery disease
  • diabetic ketoacidosis
  • diverticulitis intestinal
  • malaise
  • type 1 diabetes mellitus
  • type 2 diabetes mellitus
10+ years:
  • memory impairment
  • somnolence
  • abnormal loss of weight
  • hypoglycaemia
  • abnormal dreams
  • amnesia
  • anxiety
  • decreased appetite
  • vitamin c deficiency
  • abnormal behaviour
not specified:
  • convulsion
  • somnolence
  • dizziness
  • memory impairment
  • grand mal convulsion
  • tremor
  • anxiety
  • headache
  • mental status changes
  • weight increased

Most common drug interactions by gender *:

female:
  • convulsion
  • memory impairment
  • dizziness
  • anxiety
  • amnesia
  • hypoglycaemia
  • mental status changes
  • tremor
  • decreased appetite
  • somnolence
male:
  • convulsion
  • somnolence
  • drug ineffective
  • sedation
  • grand mal convulsion
  • granulocytopenia
  • aggression
  • weight increased
  • abnormal behaviour
  • memory impairment

Most common drug interactions by age *:

0-1:
  • convulsion neonatal
  • drug exposure during pregnancy
  • hypersomnia
  • pneumonia aspiration
  • stevens-johnson syndrome
2-9:
  • convulsion
  • aggression
  • hallucination, auditory
  • enuresis
  • somnolence
  • abnormal behaviour
  • anger
  • dehydration
  • insulin c-peptide decreased
  • lethargy
10-19:
  • convulsion
  • weight decreased
  • sedation
  • somnolence
  • abnormal behaviour
  • grand mal convulsion
  • dizziness
  • cognitive disorder
  • fall
  • memory impairment
20-29:
  • convulsion
  • granulocytopenia
  • aggression
  • anger
  • headache
  • irritability
  • confusional state
  • injury
  • somnolence
  • suicidal ideation
30-39:
  • amnesia
  • anxiety
  • memory impairment
  • abnormal dreams
  • abnormal loss of weight
  • decreased appetite
  • hypoglycaemia
  • vitamin c deficiency
  • convulsion
  • fall
40-49:
  • convulsion
  • mental status changes
  • somnolence
  • aphasia
  • back pain
  • diabetes mellitus
  • nausea
  • ataxia
  • immune reconstitution syndrome
  • multiple sclerosis relapse
50-59:
  • convulsion
  • dizziness
  • drug ineffective
  • pneumonia
  • syncope
  • asthenia
  • deep vein thrombosis
  • haematocrit decreased
  • pain
  • pyrexia
60+:
  • convulsion
  • confusional state
  • tremor
  • dizziness
  • fatigue
  • urinary tract infection
  • pneumonia
  • somnolence
  • chest pain
  • death

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Depakote er and Keppra?

Can you answer these questions?

More questions for: Depakote er, Keppra

You may be interested in these reviews

More reviews for: Depakote er, Keppra

On eHealthMe, Depakote er (divalproex sodium) is often used to treat bipolar disorder. Keppra (levetiracetam) is often used to treat epilepsy. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.